Study Name Principal Investigator
(Lung Nodule) A Study to Evaluate a Panel of Blood Biomarkers for Use in Patients Undergoing Evaluation for Lung Cancer, Onc-Ln-04 Islam, Shaheen
4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER) Abdel Karim, Nagla
A phase Ib /II trial of pembrolizumab and idelalisib in patients with non-small cell lung cancer (NSCLC) who have failed immune checkpoint inhibitor Hao, Zhonglin
AVA-CIT-330: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancer Ghamande, Sharad
CA 209-77T A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versu Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (Checkmate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evolution 77T) Abdel-Karim, Nagla
CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) Raval, Girindra
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types Ghamande, Sharad
S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)” Ghamande, Sharad
S1929, “Phase II Randomized Study of Maintenance Atezolizumab versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)” Raval, Girindra
S1933, “A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status” Raval, Girindra
RESEARCH. INNOVATION. DISCOVERY.
Augusta University
Research
AU Health
Stay Informed
Get updates on new trials and more
(706)721-6582 © Augusta University 1120 15th Street Augusta, GA 30912